|Articles|January 1, 2003

January 2003
Volume 9
Issue 1

Impact of an Antidepressant Management Program on Medication Adherence

Author(s)Lauren Hoffman, PharmD, Judy Enders, PharmD, Jiacong Luo, MD

Download PDF: Impact of an Antidepressant Management Program on Medication Adherence

Articles in this issue

over 23 years ago

Article

Effects of Ambulatory-Care Pharmacist Consultation on Mortality and Hospitalization

over 23 years ago

Article

Identifying Individuals at Risk for the Development of Type 2 Diabetes Mellitus

over 23 years ago

Article

Efficacy of Inhaled Corticosteroids Administered Once Daily for Asthma

over 23 years ago

Article

Medicaid Managed Care: Are Academic Medical Centers Penalized by Attracting Patients With High-Cost Conditions?

over 23 years ago

Article

The Cost Effectiveness of 5 Interventions to Increase Mammography Adherence in a Managed Care Population

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Impact of an Antidepressant Management Program on Medication Adherence

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

FDA Panel Backs 6 Peptides for Compounding

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Impact of an Antidepressant Management Program on Medication Adherence

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

FDA Panel Backs 6 Peptides for Compounding

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health

Boston Panel Confronts Access and Coordination Gaps in Obesity Care